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Insulin inhibits forkheadOclass (FoxO) transcription factors,
which down-regulate the expression of genes involved in me-
tabolism, cell cycle arrest, and apoptosis. After being phos-
phorylated by protein kinase B (PKB) on S253 in its DNA-
binding domain, Foxo1 is phosphorylated on T24 and
additional sites, which overall triggers its nuclear exclusion.
During this process, Foxo1 is thought to retain some tran-
scriptional activity and signaling potential. To evaluate this
Foxo1 action, we used a Foxo1-ADA mutant that is constitu-
tively nuclear due to mutation of T24 and S316 to A and har-
bors amutation of S253 to D. Adenoviral-mediated expression
of Foxo1-ADA in hepatocytes activates PKB and MAPK path-
ways more than expression of wild-type or of a transacti-
vation domain-deleted mutant (256). PKB activation can-
not be accounted for by a Foxo1-mediated increase in
upstream signaling components such as insulin receptor
substrate 1 or 2 or by Foxo1-mediated down-regulation of
Tribbles homolog 3. In contrast, Foxo1-ADA increases p38
activity, and p38 is required for effects of Foxo1 on PKB, at
least in part. We propose that Foxo1 turns on a feed-forward
loop, relayed by p38 and acting to amplify both PKB acti-
vation and Foxo1 inhibition. To conclude, key signaling
pathways are activated in hepatocytes through nuclear
Foxo1. (Endocrinology 148: 2424–2434, 2007)
FORKHEAD MEMBERS of the O class (FoxO) transcrip-tion factors consist of a family of four members, Foxo1,
Foxo3a, Foxo4, and Foxo6, serving as transcriptional end-
points of several signaling cascades. In response to growth
factors, activated protein kinase B (PKB) phosphorylates
Foxo1, Foxo3a, and Foxo4 on conserved serine/threonine
residues. It is generally believed that this leads to the reten-
tion of FoxO transcription factors in the cytoplasm, thereby
reducing the expression of their target genes (1). FoxO tran-
scription factors are involved in a wide range of events,
including cell cycle progression, cell death and metabolism,
DNA repair, protection against oxidative stress, and organ-
ismal longevity (1).
In Caenorhabditis elegans and Drosophila, deficiency in the
insulin-like pathway requires FoxO nuclear localization to
extend lifespan (2). In Drosophila, activation of the c-Jun-N-
terminal kinase (JNK) homolog pathway protects against
environmental insults and enhances longevity by counter-
acting insulin-like signaling and promoting Drosophila Foxo
nuclear localization (3). Inmammalian cells, FoxO factors are
viewed as tumor suppressors, triggering cell death or cell
cycle arrest. Interestingly, a phosphorylation-site mutant of
Foxo1 (FKHR-AAA), inwhich the threeAkt phosphorylation
sites are altered, induces cell death, whereas a similar con-
struct (FKHR-HRAAA) with a negative charge in the DNA-
binding domain, which reduces its affinity for insulin-re-
sponsive elements, fails to do so (4). Moreover, in transgenic
mice overexpressing FKHR-AAA in the liver, increased ap-
optosis is not observed (5). Taken together, these observa-
tions led us to hypothesize that the apoptotic properties of
FKHR-AAA may, in part, reflect constitutive binding to in-
sulin-responsive elements and the consequent inability to
promote a survival signal otherwise transmitted by nuclear
phosphorylated FoxO species. Notably, stress signals pro-
mote survival and relocalize FoxO factors to the nucleus
without affecting their phosphorylation on PKB target sites
(6).
Tribbles homolog 3 (TRB3) belongs to a family of pseudoki-
nase proteins acting as scaffolds, but their exact mechanisms of
action are unknown. Tribbles expression in Drosophila is re-
strained to a narrow developmental window to control the
timing and location of mitoses during gastrulation.
In adult mammals and notably humans, TRB3 expression
is physiologically restrained to the liver and is up-regulated
in tumor cells (7). Some of the hepatic functions attributed to
TRB3 such as the inhibition of PKB activity have been initially
addressed in transformed cell lines that may not represent a
physiological model to study metabolism (8, 9), and these
findings are at odds with its involvement in tumorigenesis.
Other studies conducted in primary hepatocytes have failed
to prove either a regulation of PKB by TRB3 or a modulation
of TRB3 levels by hormonal signals (10).
Matsumoto et al. (11) recently showed that overexpression
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of Foxo1-ADA or DNA-binding deficient Foxo1 (DBD-
Foxo1-ADA) activates PKB. They attributed this effect to a
reducedTRB3 expression induced by Foxo1 in primary hepa-
tocytes. However, in these cells, endogenous Foxo1 small
interfering RNA (siRNA) fails to up-regulate TRB3 levels.
Consistentwith the involvement of TRB3Drosophilahomolog
in cell cycle regulation (12) and TRB3 overexpression in hu-
man tumors (7), this may indicate that in untransformed
cells, the regulation of TRB3 expression does not solely de-
pend on Foxo1.
A recent report provides evidence that Foxo1 regulates
multiple metabolic pathways in the liver and may also mod-
ulate genes involved in cell signaling (5). Here we used
primary cultures of rat hepatocytes to ectopically express
wild-type (WT), dominant negative (256), and constitu-
tively nuclear Foxo1 mutant mimicking S253 phosphoryla-
tion (ADA). We examined the effects of these mutants on
metabolic, mitogenic, and stress signaling pathways. Con-
sistent with previous work, we found that all of these mu-
tants were able to activate PKB, in both basal and insulin-
stimulated conditions, and independently of IRS proteins.
Moreover, TRB3 overexpression in primary hepatocytes did
not affect Foxo1-induced PKB activation.
In addition to activating PKB, Foxo1mutants increased the
phosphorylation and activity of ERK, JNK, and p38. Neither
ERK nor JNK were involved in PKB activation, but p38
inhibitors and expression of dominant negative p38 reduced
Foxo1-mediated PKB activation. p38 inhibition reduced the
assembly of mammalian Target of rapamycin complex 2
(mTorc2), the recently identified PKB S473 kinase. The phe-
nomena we revealed in this study were all maximal with a
constitutively nuclear Foxo1-ADA mutant.
Materials and Methods
Adenoviruses and adenoviral transduction
Adenoviruses encoding hemagglutinin (HA)-tagged WT, domi-
nant negative (256), and constitutively nuclear (ADA) mouse Foxo1
and LacZ were generated by the Cosmid cassettes and adenoviral
DNA-Terminal Protein Complex method as described elsewhere (13).
The S253 and S316 residues of mouse Foxo1 correspond to S256 and
S319 in human Foxo1. Adenoviruses encoding HA-tagged TRB3 were
kindly provided by P. Iynedjian (Geneva School of Medicine, Geneva,
Switzerland). Adenoviruses encoding dominant negative p38 -iso-
form were purchased from Cell Biolabs (San Diego, CA). Adenovirus
production, amplification, and estimation of viral titer stocks (10)
were done in HEK-293 cells. Unless specified differently, cells were
transduced with a quantity of virus corresponding to 100 multiplicity
of infection.
Hepatocyte preparation and culture conditions
The procedures that were followed in animal studies were re-
viewed and approved by our Institutional Animal Care Committee.
WT and IRS-2 knockout immortalized neonatal mouse hepatocytes
were obtained and cultured as described (14). Primary cultures of rat
hepatocytes were isolated as described (15). Cells seeded on six-well
collagen-coated plates were allowed to attach for 4 h before adeno-
viruses were added to the medium for 2 h. Mediumwas then replaced
with serum-free Waymouth medium containing 0.2% (wt/vol) fatty-
acid-free BSA, penicillin, streptomycin, and gentamicin for 15 h.
Medium was finally replaced with Krebs-Ringer-bicarbonate buffer
containing 0.2% (wt/vol) BSA for 2.5 h before cell lysis. Wortmannin
and SP600125 were purchased from Sigma Aldrich (St. Louis, MO),
rapamycin and SB202190 were fromCalbiochem (San Diego, CA), and
U0126 was from Cell Signaling Technology (Beverly, MA). Each in-
hibitor was added 1 h before lysis. For the 24-h rapamycin treatment,
the medium was replaced after adenoviral transduction with serum-
free Waymouth medium containing 10% (vol/vol) fetal bovine se-
rum, penicillin, streptomycin, and gentamicin for 17 h and replaced
for 24 h, with rapamycin added at this time or at 1 h before lysis. When
indicated and unless specified differently, 100 nm insulin from Novo-
Nordisk (Copenhagen, Denmark) was added for 5 min before lysis.
Cells were washed with ice-cold PBS and then processed for protein
isolation.
Immunoprecipitation and Western blot
Cells were scraped and incubated for 20 min in ice-cold lysis buffer
(16). The lysates were centrifuged at 13,000  g for 20 min at 4 C, and
protein concentrations were determined by the BCA colorimetric assay
(Interchim, Montluc¸on, France). Protein A Sepharose CL-4B (Uppsala,
Sweden) was incubated with the indicated antibody or with the corre-
sponding preimmune serum for 2 h at 4 C. Then, lysates corresponding
to either 400 g (IRS-1 immunoprecipitation) or 4 mg (Rictor immuno-
precipitation) proteinwere added for 2 h at 4 C. The immunoprecipitates
were washed three times with lysis buffer, and 50 l of 4 Laemmli
buffer was added. Immunoprecipitates or 100 g total lysates were
subjected to SDS-PAGE, transferred to Immobilon-P polyvinylidene
difluoride membranes (Bedford, MA). Membranes were either pre-
soaked in blocking buffer or directly incubated in blocking buffer con-
taining antibodies, according to the manufacturer’s instructions.
Antibodies
The antibodies to phosphorylated tyrosine residues (no. 05-321),
IRS-1 (no. 06-248), IRS-1 phospho-Ser307 (no. 07-247), IRS-2 (no. 06-506),
p85 -subunit (no. 05-217), and ERK1/2 (no. 06-182) were from Upstate
Biotechnology (Lake Placid, NY). Antibodies directed to the HA epitope
(no. H6533) and -tubulin (no. T4026) were from Sigma Aldrich. The
antibody directed to Foxo1 (no. sc-11350) was from Santa Cruz Biotech-
nology (Santa Cruz, CA). The antibody directed to TRB3 (no. ST1032)
was fromCalbiochem (SanDiego, CA). The antibodies directed to Rictor
used for immunoprecipitation and for Western blotting were, respec-
tively, from Bethyl Laboratories (Montgomery, TX; no. BL2178) and
Abnova Corp. (Heidelberg, Germany; no. 1F3). Other antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
RNA isolation and quantitative real-time PCR analysis
Total RNA was isolated by standard procedures, treated with
DNase (Ambion, Austin, TX), and reverse transcribed using the re-
verse transcription system kit (Promega, Madison,WI). PCRwere run
in triplicate using SYBR Green I Master Mix Plus (Eurogentec, Se-
raing, Belgium) and quantitated using the ABI Prism 7700 sequence
detection system (Applied Biosystems, Courtaboeuf, France) accord-
ing to the manufacturer’s instructions. PCR primers for each gene
were designed using Primer Express software (Applied Biosystems),
and sequences used to quantify TRB3 and HPRT mRNA were as
follows: rat TRB3 sense, 5-CTC AAG TTG CGT CGA TTT GTC T-3,
and antisense, 5-CAC CAA CTT CGT CCT CTC ACA GT-3; mouse/
rat HPRT sense, 5-TGA AAG ACT TGC TCG AGA TGT CA-3, and
antisense, 5-AAA GAA CTT ATA GCC CCC CTT GA-3. Cycle
threshold values were normalized to HPRT expression, and results
are expressed as a fold change of mRNA compared with the LacZ
condition, which was arbitrarily assigned a value of 1.
The siRNA experiments
Knockdown of endogenous Foxo1 was performed in primary rat
hepatocytes using the JetPEI hepatocyte transfection reagent (Polyplus
Transfection SA, Illkirch, France) and 100 nm of a nonspecific oligonu-
cleotide duplex or a duplex of the following targeting oligonucleotides:
Foxo1 sense, 5-CCGCCAAACACCAGUCUAATT-3; Foxo1 antisense,
5-UUAGACUGGUGUUUGGCGGTT-3. Cells were lysed and pro-
cessed for Western blot analysis 48 h after transfection.
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In vitro PKB kinase assays
The in vitro kinase activity of immunoprecipitated PKB toward re-
combinant glycogen synthase kinase 3 (GSK3) was determined in pri-
mary hepatocytes and IRS-2 knockout immortalized neonatal mouse
hepatocytes with a nonradioactive Akt kinase assay kit (no. 9840; Cell
Signaling Technology) according to the manufacturer’s instructions.
Glycogen synthesis
The effect of Foxo1-ADA on glycogen synthesis was assessed by
measuring the incorporation of [3H]glucose into glycogen. Briefly, over-
night starved primary hepatocytes in Krebs-Ringer-bicarbonate buffer
containing 0.2% (wt/vol) BSAwere added to 100 nm insulin, 10mm cold
glucose, and 0.2 m [3H]glucose for 1 h. Cells were then scraped in 300
l of a 30% (vol/vol) potassium hydroxide solution and heated at 100
C for 15 min, and glycogen was precipitated overnight at 20 C in a
200-l 2% (vol/vol) Na2SO4 solution. After a wash in 66% (vol/vol)
absolute ethanol, precipitated glycogen was dissolved in 300 l water,
and [3H]glucose incorporationwas determined by scintillation counting.
Statistical analysis
Experiments performed at least three times are presented as mean
values  sem, and P values were determined by unpaired Student’s t
test. Results were considered significant for P  0.05.
Results
Foxo1 stimulates PKB through phosphatidylinositol 3-
kinase (PI3K) and mTorc2, independently of TRB3
Ectopic expression of wild-type and Foxo1 mutants in pri-
mary cultures of rat hepatocytes increases the phosphorylation
of PKB on threonine 308 (not shown) and serine 473 but does
not alter PKB expression (Fig. 1, A and B). Consistent with PKB
activation, we observed increased phosphorylation of wild-
type and 256-Foxo1 on T24 (Fig. 1B), the PKB target site re-
sponsible for FoxO nuclear exclusion (17). In contrast, phos-
phorylation of Foxo1-ADA on T24 was not detected (Fig. 1B).
Furthermore, the in vitro activity of immunoprecipitated PKB
FIG. 1. Foxo1 stimulates PKB activity. A, Quan-
tification of total or S473-phosphorylated PKB as-
sessed byWestern blots (W.B.) in primary cultures
of hepatocytes infected with LacZ, WT, 256, or
ADA Foxo1 expression vectors (n  3). Results
were normalized by assigning a value of 1 to the
LacZ condition.*, Statistically different from the
control LacZ condition; **, statistical difference
between Foxo1-infected conditions; N.S., not sig-
nificant. B, Representative Western blot showing
the relative level of endogenous and ectopic Foxo1,
Foxo1 T24 phosphorylation, total PKB, and S473-
phosphorylated PKB in primary cultures of hepa-
tocytes not infected (A) or infected with LacZ, WT,
256, or ADA Foxo1 expression vectors. The 256
form of Foxo1 lacks the epitope recognized by the
Foxo1 antibody. C, Western blots showing the in
vitro kinase activity of immunoprecipitated PKB
fromprimary cultures of hepatocytes infectedwith
LacZ or ADA Foxo1 expression vectors and left
untreated or stimulated for 5 min with 100 nM
insulin before lysis (n  3). D, Quantification of
insulin-stimulated glycogen synthesis in primary
cultures of hepatocytes infected with LacZ or ADA
Foxo1 expression vectors (n  3). Results were
normalized by assigning a value of 1 to the LacZ
condition.*, Statistically different from the control
LacZ condition.
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toward recombinant GSK3 protein was increased by Foxo1-
ADA in basal and insulin-stimulated cells (Fig. 1C). Accord-
ingly, in vivo glycogen synthesis was increased by Foxo1-ADA
expression upon insulin treatment (Fig. 1D).
Consistent with the idea that Foxo1 uses components of
the insulin signaling pathway to activate PKB, wortmannin
treatment abolished its effects (Fig. 2A). However, addition
of insulin to Foxo1-ADA-infected cells still significantly in-
creased PKB phosphorylation. Also, PKB phosphorylation-
mediated Foxo1-ADA was increased by a short (1-h) rapa-
mycin treatment, compared with Foxo1-ADA-untreated
cells. In agreement with mTorc2 being the genuine PKB S473
kinase (18), a 24-h rapamycin treatment, which has recently
been shown to inhibit both PKB and mTorc2, blunted the
phosphorylation of PKB S473 induced by Foxo1-ADA (19).
The physiological role of endogenous Foxo1 in the regulation
of PKB activity was confirmed by Foxo1 siRNA, which re-
duced insulin-stimulated phosphorylation of PKB on S473
(Fig. 2, B and C).
Ectopic expression of WT and Foxo1 mutants decreased
the mRNA and endogenous protein levels of TRB3 (Fig. 3, A
and B). Using adenoviral expression of TRB3 in primary rat
hepatocytes, Iynedjian (10) failed to provide evidence for a
role of TRB3 as an inhibitor of insulin-mediated PKB acti-
vation. Consistent with this, we found in the same cells that
coexpression of TRB3 with Foxo1-ADA did not affect PKB
phosphorylation, indicating that Foxo1 does not activate
PKB by down-regulating TRB3 (Fig. 3C).
In summary,wild-type,256, andADAFoxo1 proteins are
able to activate PKB in hepatocytes through PI3K and
mTorc2, albeit with different potencies, and independently
of TRB3.
Foxo1 activates ERK, JNK, and p38
It has been recently reported that, in addition to PKB, both
the ERK and p38 kinases phosphorylate Foxo1 and regulate
its activity (20). As part of a newly identified regulatory loop,
FIG. 2. Foxo1 stimulates PKB through PI3K
and mTorc2. A, Upper panel, quantification of
the effect of different treatments on PKB
Ser473 phosphorylation in primary cultures of
hepatocytes infected with LacZ or ADA Foxo1
expression vectors (n  4). Results were nor-
malized by assigning a value of 1 to the un-
treated LacZ condition.*, Statistical difference
between LacZ and ADA when subjected to the
same treatment; **, statistical difference be-
tween treatments; N.S., not significant. Lower
panel, a representative Western blot (W.B.) is
shown. B, Western blot showing the relative
level of endogenous Foxo1 and S473-phosphor-
ylated PKB in primary cultures of hepatocytes
transfected with control or Foxo1 siRNA in
basal and insulin-stimulated conditions. C,
Quantification of the effect of Foxo1 siRNA on
endogenous Foxo1 expression and PKB Ser473
phosphorylation in primary cultures of hepato-
cytes in insulin-stimulated conditions (n  3).
Resultswere normalized by assigning a value of
1 to the control condition.*, Statistically differ-
ent from the control condition.
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we found that in turn, ectopic expression of WT and Foxo1
mutants in primary cultures of rat hepatocytes increased the
phosphorylation of ERK1/2, JNK1/2, and p38 without af-
fecting their respective expression levels (Fig. 4, A and B).
Another recent study showed that multiple pathways can
lead to p38 activation in addition to the canonical MAPK
kinase (MEK) MKK3/6 (MEK 3/6)-p38 pathway (21). Con-
sistent with this notion, in comparisonwith the LacZ control,
Foxo1-ADA did not increase the phosphorylation of p38 and
ERK1/2 respective upstream kinases, MKK3/MKK6 and
MEK1/2 (Fig. 4C and D).
Foxo1 effects on IRS proteins
As described previously (22), we found that WT and mu-
tant Foxo1 increased IRS-2 expression, up to 5-fold for the
Foxo1-ADAmutant (Fig. 5, A and B). Because up-regulation
of IRS-2 may enhance insulin signaling (23, 24), we ruled out
IRS-2 involvement in PKB activation using immortalized
neonatal hepatocytes isolated from WT mice and mice with
the IRS-2 gene deleted. Foxo1-ADA still significantly in-
creased PKB phosphorylation in IRS-2 knockout cells, com-
paredwith the LacZ control,with no compensatory effects on
IRS-1 (Fig. 5, C andD). Foxo1-ADA also increased the in vitro
activity of PKB immunoprecipitated from basal and insulin-
stimulated IRS-2 knockout hepatocytes (Fig. 5E). In rat hepa-
tocytes, Foxo1-ADA increased IRS-1 expression but did not
enhance its tyrosine phosphorylation or association with
p85 (Fig. 6, A–C). This may be due to the concomitant
increase in IRS-1 serine phosphorylation induced by Foxo1-
ADA (Fig. 6, B and C), because serine phosphorylation of
IRSs is thought to reduce IRS-1/p85 association and hence
insulin action (25). These results suggest that neither IRS-1
nor IRS-2 is involved in Foxo1-mediated PKB activation.
P38 is involved in Foxo1-mediated PKB activation
Because JNK and p38 have been shown to enhance PKB
activation (26), we asked whether Foxo1-induced PKB stim-
ulation involved crosstalk between MAPK and PKB (Fig. 7).
Using specific chemical inhibitors, we found that neither
ERK1/2 nor JNK1/2 appears to be involved in PKB activa-
tion (Fig. 7, A and B). ERK1/2 blockade by the MEK1/2
inhibitor U0126 was confirmed by the decrease in ERK1/2
phosphorylation. The JNK1/2 ATP competitor SP600125 did
not modify JNK1/2 phosphorylation (not shown) but re-
duced its activity as judged by the phosphorylation of c-Jun
(Fig. 7B).
In contrast, we found that p38 inhibition with SB202190
reduced Foxo1-mediated PKB activation (Fig. 7, A and B).
Coexpression of a nonphosphorylatable dominant negative
p38 -isoform together with Foxo1-ADA inhibited endoge-
nous p38 and PKB phosphorylation (Fig. 7, C andD). Finally,
we investigatedwhethermTorc2was involved in Foxo1- and
p38-mediated PKB activation. As shown on Fig. 8A, Foxo1-
ADA increased the expression level of Rictor in primary
hepatocytes. Moreover, mTor association with Rictor is in-
creased by Foxo1-ADA and reduced by p38 inhibition with
SB202190 (Fig. 8B).
Discussion
Given their role in a large array of signaling events, FoxO
factors are likely to participate in the coordinated response
of cells to changes in environmental conditions. Consistent
with this view, we found that ectopic Foxo1 expression in
hepatocytes activates PKB, ERK, JNK, and p38, without af-
fecting their expression level (Figs. 1, A and B, and 4, A and
B). Increased basal activity of ERK, JNK, and p38 is thought
to participate in insulin resistance (27). Constitutive activa-
tion of these kinases increases IRS-1 and IRS-2 protein levels
but reduces PKB activation (28). In rat hepatocytes ectopi-
cally expressing Foxo1, we also found an increase in IRS-1
and IRS-2 protein levels and in IRS-1 serine phosphorylation
on sites previously associated with reduced insulin action
(Figs. 5, A and B, and 6, A–C). However, upon Foxo1-ADA
expression, we did not detect a substantial decrease in IRS-1
tyrosine phosphorylation or in IRS-1 association to p85 (Fig.
FIG. 3. Foxo1 stimulates PKB independently of TRB3. A, Quantifi-
cation of TRB3 mRNA level assessed by quantitative RT-PCR in
primary cultures of hepatocytes infected with LacZ, WT, 256, or
ADA Foxo1 expression vectors (n  3). Results were normalized by
assigning a value of 1 to the LacZ condition.*, Statistically different
from the control LacZ condition. B, Representative Western blot
showing the relative level of endogenous TRB3 in primary cultures of
hepatocytes infected with LacZ (A) or increasing amount of ADA
Foxo1 expression vector (n  3). C, Representative Western blot
showing the relative levels of total PKB and of S473-phosphorylated
PKB in primary cultures of hepatocytes infected with LacZ or Foxo1-
ADA or coinfectedwith both Foxo1-ADAandTRB3 expression vectors
(n  3).
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6A). Recent data (29, 30) and ours here presented suggest that
the concept of insulin resistance induced by IRS-1 serine
phosphorylation should be viewedwith cautionwhenmech-
anisms leading to increased insulin signaling act down-
stream of IRS molecules. This is apparent, for example, from
our findings showing that PKB activity was increased by
Foxo1 despite increased serine phosphorylation of IRS-1. At
first glance, Foxo1-mediated up-regulation of IRS-2 ap-
peared as an attractivemechanism bywhich it could enhance
hepatic insulin signaling (24). However, we excluded this as
being the sole possibility in Foxo1-ADA-infected hepatocytes
that were isolated from IRS-2 knockout mice (Fig. 5, C–E).
Conflicting results exist as to whether TRB3 is modulated
during the fasting-feeding transition and acts to dampen
insulin signaling and PKB activation in the liver. One pos-
sibility is that these discrepancies may be attributable to the
use of transformed cellular systems (8, 9). Iynedjian (10)
conducted studies in primary hepatocytes that failed to
prove either a regulation of PKB by TRB3 or a modulation of
TRB3 levels by hormonal signals.
Matsumoto et al. (11) showed that Foxo1-ADA promotes
PKB phosphorylation and reduces TRB3 expression in pri-
mary hepatocytes in a DNA-binding-independent manner.
However, in these cells, endogenous Foxo1 siRNA fails to
up-regulate TRB3 levels (11). The notion that TRB3 is up-
regulated in human tumors is at odds with its presumed
functions on PKB. Ectopic expression of TRB3 in our condi-
tions did not affect PKB stimulation induced by Foxo1 (Fig.
3C).
We found that inhibition of p38, but not of ERK or JNK,
reduces PKB activation induced by Foxo1 expression (Fig. 7).
In agreement with a recent report (20), our results suggest
that the stress kinase p38 may also modulate FoxO phos-
phorylation through PKB activation. The search for the
hypothetical phosphoinositide-dependent kinase-2, which
phosphorylates PKB on serine 473, has led to the implication
of several kinases such as p38 and JNK (26). However, more
recent efforts have identified mTorc2 as the most likely gen-
uine phosphoinositide-dependent kinase-2 (18). Very recent
reports have shown that at least three different mTorc2 com-
plexes are able to activate PKB, one of which may be regu-
lated by stress signals (31, 32). Our findings suggest that
Foxo1 and p38 activate PKB by up-regulating Rictor expres-
sion and increasing mTorc2 assembly (Fig. 8). Also, two
recent reports have suggested that Rictor phosphorylation
may control mTorc2 assembly (33, 34). Our results strongly
suggest that Rictor may be a substrate of p38.
PKB phosphorylation on S473 by mTorc2 has been shown
to be required for Foxo1 T24 phosphorylation but not for
most other effects downstream of PKB including GSK3 or
Foxo1 S253 phosphorylation (33, 35, 36). Althoughwedo find
an increase in the in vitro PKB kinase activity toward a GSK3-
peptide in Foxo1-ADA-infected primary hepatocytes, the
level of S473-phosphorylated PKB did not fully correlate
with its ability to phosphorylate GSK3 (Fig. 1C). Compared
with unstimulated Foxo1-ADA-infected cells, insulin-treated
control conditions exhibited an increase in PKB phosphor-
ylation on S473 but displayed reduced T308 phosphorylation
FIG. 4. Foxo1 activates ERK, JNK, and
p38. A, Quantification of total or phosphor-
ylated ERK, JNK, and p38 assessed by
Western blots (W.B.) in primary cultures of
hepatocytes infected with LacZ, WT, 256,
or ADA Foxo1 expression vectors (n  3).
Results were normalized by assigning a
value of 1 to the LacZ condition.*, Statis-
tically different from the control LacZ con-
dition; **, statistical difference between
Foxo1-infected conditions. B, Representa-
tive Western blots showing the levels of
total or phosphorylated ERK, JNK, and
p38 in primary cultures of hepatocytes in-
fected with LacZ, WT, 256, or ADA Foxo1
expression vectors. C and D, Western blots
showing the respective level of activation of
p38 or ERK upstream kinases in primary
cultures of hepatocytes infected with LacZ
or Foxo1-ADA expression vectors (n  3).
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and kinase activity. In contrast, in transformed hepatocytes,
PKB phosphorylation on S473 mirrored that of T308 and its
activity (Fig. 5E).
One possible explanation suggested by Guertin et al. (33)
may be that in primary cells, PKB phosphorylation on T308
is less dependent on its previous phosphorylation on S473
than in transformed cells. Thismay indicate that PKB activity
in tumor cells may be more sensitive to mTorc2 inhibition
than in normal cells.
Another interesting conclusion that can be drawn fromour
experiments in primary hepatocytes is that Foxo1-ADA
seems to increase the level of basal and insulin-stimulated
phosphorylation of PKB on T308 relative to that of S473,
compared with insulin-stimulated control conditions. As-
suming thatmost of insulin’s metabolic effects depend solely
on T308, this may be indicative of an unexpected insulin-
sensitizing effect of Foxo1-ADA. Our findings that Foxo1-
ADA increases insulin-stimulated glycogenesis are consis-
tent with this view (Fig. 1D).
Remarkably, p38 activation in the liver is increased dur-
ing fasting (37) and in diabetic mice models (38). cAMP
response element binding protein phosphorylation and
peroxisome proliferator-activated receptor- coactivator
1 expression, which are necessary to turn on the glu-
coneogenic program, have been shown to be dependent on
p38 stimulation (37). In addition, it has been reported that
p38-mediated phosphorylation of CCAAT/enhancer
binding protein  increases phosphoenolpyruvate car-
boxykinase transcription in the liver (38). During fasting,
low insulin levels and activated p38 may partially stim-
FIG. 5. Foxo1-mediated activation of PKB in
IRS-2/ hepatocytes. A, Quantification of
IRS-2 protein level assessed byWestern blots in
primary cultures of hepatocytes infected with
LacZ, WT, 256, or ADA Foxo1 expression vec-
tors (n 4). Results were normalized by assign-
ing a value of 1 to the LacZ condition.*, Statis-
tically different from the control LacZ condition;
**, statistical difference betweenFoxo1-infected
conditions. B, Representative Western blot
showing the level of IRS-2 in primary cultures of
hepatocytes infected with LacZ, WT, 256, or
ADA Foxo1 expression vectors. C, Quantifica-
tion of S473-phosphorylated PKB and of IRS-1
protein level fromWestern blots (W.B.) ofWT or
IRS-2/ immortalized mouse hepatocytes in-
fected with LacZ or ADA Foxo1 expression vec-
tors (n 3). Results were normalized by assign-
ing a value of 1 to the LacZ condition in IRS-2
WT cells.*, Statistically different from the LacZ
condition in the same cell line; **, statistical
difference between Foxo1-infected conditions.
D, RepresentativeWestern blot showing the rel-
ative levels of endogenous and ectopic Foxo1,
IRS-1, IRS-2, and total and phosphorylated
PKB in WT or IRS-2/ immortalized mouse
hepatocytes infected with LacZ or Foxo1-ADA
expression vectors. E, Western blots showing
the in vitro kinase activity of immunoprecipi-
tated PKB from IRS-2/ immortalized mouse
hepatocytes infected with LacZ or ADA Foxo1
expression vectors and left untreated or stimu-
lated for 5 min with 100 nM insulin before lysis
(n  3).
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ulate PKB, which in turn is able to phosphorylate Foxo1 on
S253 but not to exclude it from the nucleus. Consequently,
Foxo1 and p38 may together activate the gluconeogenic
and/or prosurvival program. When feeding and the sub-
sequent rise in circulating insulin level occur, both p38 and
PKB may act together to switch off Foxo1 through its
phosphorylation on T24. Given our finding that Foxo1 is
able to activate both PKB and MAPK, the benefit of this
could be that during periods of starvation, a positive feed-
forward loop shifts Foxo1 activity to enhance survival and
FIG. 7. p38 is involved in Foxo1-mediated PKB acti-
vation. A, Quantification of the effect of different
treatments on PKB Ser473 phosphorylation in pri-
mary cultures of hepatocytes infected with LacZ or
ADA Foxo1 expression vectors (n  3). Results were
normalized by assigning a value of 1 to the untreated
LacZ condition.*, Statistical difference between LacZ
and ADA when subjected to the same treatment. B,
Representative Western blots showing the relative
levels of total and phosphorylated PKB and ERK and
of phosphorylated c-Jun upon different treatments in
primary cultures of hepatocytes infected with LacZ or
ADA Foxo1 expression vectors. C, Quantification of
phosphorylated PKB or p38 from Western blot for
primary cultures of hepatocytes infected with LacZ or
Foxo1-ADA or coinfected with Foxo1-ADA and either
LacZ or p38 dominant negative (p38 DN) expression
vectors (n 3). Results were normalized by assigning
a value of 1 to the LacZ condition.*, Statistically dif-
ferent from the control LacZ condition; **, statistical
difference between ADA-infected conditions. D, Rep-
resentativeWestern blot showing the relative levels of
Foxo1-ADA, phosphorylated PKB and p38, and en-
dogenous and ectopic total p38 in primary cultures of
hepatocytes infected with LacZ or Foxo1-ADA or coin-
fected with Foxo1-ADA and either LacZ or p38 dom-
inant negative (p38 DN) expression vectors. DMSO,
Dimethylsulfoxide.
FIG. 6. Foxo1-mediated activation of PKB is independent of
IRS-1. A, Upper panel, immunoprecipitation (IP) with IRS-1
or preimmune (PI) serum from rat hepatocyte primary cul-
ture lysates (400 g). Cells were infected with LacZ or Foxo1-
ADA expression vectors and left untreated or stimulated for
5 min with 100 nM insulin before lysis. Immunoprecipitates
were analyzed as described (n 2).Lower panel,Western blot
(WB) analysis of 100 g protein of the corresponding total
lysates. B,Western blot of total lysates from primary cultures
of hepatocytes infected with LacZ or Foxo1-ADA expression
vectors showing the level of total and S636-phosphorylated
IRS-1 in basal and insulin-stimulated conditions (n  3). C,
Quantification of total and S307-, S636-, and S612-phosphor-
ylated IRS-1 levels from Western blots for primary cultures
of hepatocytes infected with LacZ or Foxo1-ADA expression
vectors (n 3). Results were normalized by assigning a value
of 1 to the LacZ condition.*, Statistically different from the
control LacZ condition.
Naı¨mi et al. • Nuclear FoxO Controls Key Signaling Pathways Endocrinology, May 2007, 148(5):2424–2434 2431
 by on May 28, 2010 endo.endojournals.orgDownloaded from 
gluconeogenesis, until PKB activation reaches a threshold
driving Foxo1 nuclear exclusion. Such a scenario may also
protect against unrestrained PKB activity.
Our data suggest that the phosphorylation of PKB on S473
and of Foxo1 on T24 are tightly coupled and are part of the
same regulatory loop. In our experimental conditions, WT
and256-Foxo1 activate PKB to a similar degree,whereas the
constitutively nuclear ADA mutant was more potent (Fig.
1B). The stronger action of the ADA mutant compared with
WT and 256-Foxo1 may reflect the fact that once PKB is
activated, WT Foxo1 and 256-Foxo1 become phosphory-
lated on both S253 and T24 and are excluded from the nu-
cleus (Fig. 1C) (17).
Foxo1 transactivating potential involves protein-protein
interactions or post-translational modifications that may be
specific for WT, 256, or ADA-Foxo1 proteins. Our finding
that 256 Foxo1 also activates PKB may indicate that the
transactivation domain of Foxo1 is not required and that the
shared effects of Foxo1 mutants may imply an active repres-
sion of gene transcription at specific promoters (4). On the
other hand, the lesser effects of this mutant compared with
Foxo1-ADA may indicate a requirement for the transactiva-
tion domain. As recently shown for the phosphoenolpyru-
vate carboxykinase promoter (39), it should be noted that
endogenous and phosphorylated Foxo1 still interacts with
IRS sequences, and the same may hold true for Foxo1-ADA,
either directly or through protein-protein interactions. In-
terestingly, it has been shown that when Foxo1 is mainly
cytosolic and phosphorylated, it interacts with and inhibits
Tuberous Sclerosis Complex 2, promotingmTorc1 activation
(40). This may be relevant to our study because some authors
have suggested a competition between raptor and rictor for
mTor binding (41, 42).Hence, the cytosolic localization ofWT
and 256-Foxo1 in our model may explain their reduced
ability to activate mTorc2 and PKB.
Given the fact that FoxO transcription factors are involved
in a gamut of important biological programs, it is not sur-
prising that mechanisms have been built in to thwart their
activity. The circuitries we have revealed here are likely to
participate in the coordinated cellular responses to changes
in FoxO functions.
Our data provide only a glimpse into the regulation of the
FoxO transcription factors, because it involves not only phos-
phorylation but also acetylation and ubiquitination. The
Foxo1-ADAmutant behaves as if it were phosphorylated on
S253. Similar to acetylation of the FoxO factors, which acts as
a switch controlling their apoptotic and survival properties
(43, 44), increases their phosphorylation on S253, and may
reduce their binding to DNA (45, 46), we propose that in-
sulin-mediated phosphorylation of Foxo1 on S253 stimulates
its potential to activate PKB and the MAPK pathways. How-
ever, additional studies are needed to evaluate the role of
phosphorylation at this site.
A major challenge is to put the regulation loops we have
identified in the broader network of the interplay between
FoxO and the pathways it regulates and bywhich it is in turn
modulated. Identification of alterations in these mutually
regulating interactions is likely to contribute to a better un-
derstanding of several humandisease conditions. In addition
to their well-established metabolic functions, our data sug-
gest that FoxO factors may be involved in tumorigenesis.
Indeed, FoxO fusion transcripts found in both leukemias and
alveolar rhabdomyosarcomas always possess disruptions in
their DNA-binding domain, and they have been shown to
activate the oncogenic potential of the translocations (47).
Finally, as already shown for another Forkheadmember (48),
our results with Foxo1-ADAmay explain the permissive role
of insulin on liver regeneration because PKB (49), ERK (50),
and JNK activation (51) and increased caveolin1 expression
(52, 53) have been involved in this process.
Together, our data show that several major signaling path-
ways can be activated in hepatocytes through nuclear Foxo1.
Dampening of these pathways would take place only with
Foxo1 phosphorylation on T24. Similar to the dual role of
Foxo1 in controlling hepatic metabolism, our data argue for
a dual role of Foxo1 in death and survival control. Such a
scenario reveals an unexpected role for Foxo1 in amplifying
metabolic, survival, mitogenic, and stress signals and sug-
FIG. 8. Involvement of p38 in mTorc2 assembly. A, Quantification of
Rictor protein level assessed by Western blots (W.B.) in primary
cultures of hepatocytes infected with LacZ or ADA Foxo1 expression
vectors (n  4). Results were normalized by assigning a value of 1 to
the LacZ condition.*, Statistically different from the control LacZ
condition. B, Upper panel, immunoprecipitation with Rictor or non-
immune serum from rat hepatocyte primary culture lysates (4 mg).
Cells were infected with LacZ or Foxo1-ADA expression vectors and
left untreated or stimulated for 30 min with 20 M SB202190 before
lysis. Immunoprecipitates were analyzed as described (n 2). Lower
panel, Western blot analysis of 100 g protein of the corresponding
total lysates.
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gests the existence of multiple feedback loops by which
Foxo1 integrates and controls these pathways.
In conclusion, Foxo1 appears to regulate multiple aspects
of liver physiology, including development, metabolism,
survival, proliferation, and maybe regeneration.
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